PURPOSE: We performed a meta-analysis of three sub-studies of the randomized Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial to determine the effects of exemestane and tamoxifen on bone health. METHODS: Patients received exemestane or tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed at baseline and after 12 and 24 months of treatment. Bone turnover markers were also measured. RESULTS: Patients receiving tamoxifen showed a mean increase from baseline in lumbar spine BMD of 1.2% at month 12 and 0.2% at month 24. Patients receiving exemestane showed a mean decrease from baseline of 2.6% after 12 months and 3.5% after 24 months. There were significant differences in the changes in lumbar spine BMD between treatment groups (P < 0.0001 at both time points). Changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen (P < 0.05 at both time points). Bone turnover markers decreased from baseline with tamoxifen and increased with exemestane. CONCLUSIONS:Exemestane resulted in decreases in BMD and increases in bone turnover markers. BMD increased and bone turnover markers decreased with tamoxifen.
RCT Entities:
PURPOSE: We performed a meta-analysis of three sub-studies of the randomized Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial to determine the effects of exemestane and tamoxifen on bone health. METHODS:Patients received exemestane or tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed at baseline and after 12 and 24 months of treatment. Bone turnover markers were also measured. RESULTS:Patients receiving tamoxifen showed a mean increase from baseline in lumbar spine BMD of 1.2% at month 12 and 0.2% at month 24. Patients receiving exemestane showed a mean decrease from baseline of 2.6% after 12 months and 3.5% after 24 months. There were significant differences in the changes in lumbar spine BMD between treatment groups (P < 0.0001 at both time points). Changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen (P < 0.05 at both time points). Bone turnover markers decreased from baseline with tamoxifen and increased with exemestane. CONCLUSIONS:Exemestane resulted in decreases in BMD and increases in bone turnover markers. BMD increased and bone turnover markers decreased with tamoxifen.
Authors: William R Miller; John Bartlett; Angela M H Brodie; Robert W Brueggemeier; Enrico di Salle; Per Eystein Lønning; Antonio Llombart; Nicolai Maass; Thierry Maudelonde; Hironobu Sasano; Paul E Goss Journal: Oncologist Date: 2008-08-11
Authors: J G H van Nes; C Seynaeve; S Jones; C Markopoulos; H Putter; C J H van de Velde; A Hasenburg; D W Rea; J-M Vannetzel; L Dirix; Y Hozumi; M J Kerin; D G Kieback; W M Meershoek-Klein Kranenbarg; E T M Hille; J W R Nortier Journal: Br J Surg Date: 2010-05 Impact factor: 6.939
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: P Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin Journal: Ann Oncol Date: 2008-04-29 Impact factor: 32.976
Authors: M Rabaglio; Z Sun; K N Price; M Castiglione-Gertsch; H Hawle; B Thürlimann; H Mouridsen; M Campone; J F Forbes; R J Paridaens; M Colleoni; T Pienkowski; J-M Nogaret; I Láng; I Smith; R D Gelber; A Goldhirsch; A S Coates Journal: Ann Oncol Date: 2009-05-27 Impact factor: 32.976
Authors: Richard Eastell; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Paul E Goss; Dawn L Hershman; Angela M Cheung; James N Ingle; Sundeep Khosla; Vered Stearns; Haji Chalchal; Kendrith Rowland; Hyman B Muss; Hannah M Linden; Judite Scher; Kathleen I Pritchard; Catherine R Elliott; Tanja Badovinac-Crnjevic; Jessica St Louis; Judith-Anne W Chapman; Lois E Shepherd Journal: Lancet Oncol Date: 2014-03-11 Impact factor: 41.316
Authors: Ioannis Kyvernitakis; Tilman D Rachner; Anja Urbschat; Olaf Hars; Lorenz C Hofbauer; Peyman Hadji Journal: J Cancer Res Clin Oncol Date: 2014-06-07 Impact factor: 4.553
Authors: Michael Gnant; Jose Baselga; Hope S Rugo; Shinzaburo Noguchi; Howard A Burris; Martine Piccart; Gabriel N Hortobagyi; Janice Eakle; Hirofumi Mukai; Hiroji Iwata; Matthias Geberth; Lowell L Hart; Peyman Hadji; Mona El-Hashimy; Shantha Rao; Tetiana Taran; Tarek Sahmoud; David Lebwohl; Mario Campone; Kathleen I Pritchard Journal: J Natl Cancer Inst Date: 2013-02-19 Impact factor: 13.506